Outcome of Frontline Treatment with Generic Imatinib In Adult Patients with Chronic Myeloid Leukemia in Algerian Population: A Multicenter Study

摘要

IntroductionIn a developing country like Algeria, such expensive therapy is not available. Alternative approaches are needed to help these adult. In Algeria ‘imatib’ (CIPLA-India) was introduced in 2006; but no study has been published yet in the North Africa region regarding response and outcome of this copy in CML patients. The goal of this multicenter study is to characterize newly adult CML in the western region of Algeria and to assess the effectiveness and safety of imatib (IM, copy) as frontline therapy for patients with CML.